Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant gemcitabine + cisplatin versus immediate radical surgery for incidental gallbladder carcinoma or biliary tract cancer
2017-004444-38Phase 3Completed
- Sponsor
- Krankenhaus Nordwest
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin and gemcitabine in gallbladder cancer, biliary cancer, intrahepatic cholangiocarcinoma (ICC) and 1 more (2 arms), sponsored by Krankenhaus Nordwest. Primary endpoint: Overall survival. Started Sep 2018; status: completed.
02
Drugs
cisplatingemcitabine
03
Conditions
gallbladder cancerbiliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2017-004444-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004444-38.